NasdaqGS:STOKBiotechs
Is It Too Late To Revisit Stoke Therapeutics (STOK) After A 226% One-Year Surge?
If you are wondering whether Stoke Therapeutics at around US$30.97 is still offering value or already pricing in a lot of optimism, you are not alone.
The stock has seen a 226.3% return over the last year, although the past 7 days and 30 days brought declines of 11.9% and 6.1% respectively, and year to date it is close to flat at 0.2%.
Recent attention on Stoke Therapeutics has centered on its position in the pharmaceuticals and biotech space, where investors often react quickly to clinical...